Log in using OpenID

COPD Drugs Market Share, Size, Price, Growth, Trends and Forecasts 2016 – 2020

Technavio recognizes the following companies as the key players in the COPD drugs market in China: AstraZeneca, Boehringer Ingelheim, GSK, Merck, and Novartis.
Market Reports Center
One Stop Market Research Shop
COPD Drugs Market Share, Size, Price, Growth, Trends and
Forecast 2016 – 2020
Technavio Announces the Publication of its Research Report – COPD Drugs Market in China 2016-2020
Technavio recognizes the following companies as the key players in the COPD drugs market in China:
AstraZeneca, Boehringer Ingelheim, GSK, Merck, and Novartis.
Other Prominent Vendors in the market are: Ache Laboratorios Farmaceuticos, Almirall, Aquinox
Pharmaceuticals, Ario Pharma, BioMarck Pharmaceuticals, Gilead Sciences, Mereo BioPharma Group,
Mylan, Orion, Pearl Therapeutics, Prosonix, Teva Pharmaceutical Industry, Theravance Biopharma,
Theron Pharmaceuticals, Verona Pharma, Xention, and ZAI Lab.
Download Brochure now @
Commenting on the report, an analyst from Technavio’ s team said: “A key trend which is boosting
market growth is the increased focus on combination therapies. Combination therapies have a better
advantage over monotherapies in providing better efficacy in the treatment of a condition.
Manufacturers are now concentrating on developing combination therapies to treat COPD.These
combination therapies reduce COPD-related hospitalizations and bring out better treatment outcomes
in patients. Thus, the development of combinations therapies will increase the patient compliance
toward the uptake of medications and help in the growth of the market.”
According to the report, pollutants such as ground-level ozone, carbon dioxide, smog, fumes from
vehicles, and particulates such as dust, soot, and pollen grains are known to trigger diseases such as
COPD, asthma, bronchitis, and other respiratory issues. Airborne particles, sulfur dioxide, and nitrogen
oxide are critical environment pollutants that worsen respiratory symptoms. Rapid globalization,
urbanization, and industrialization have led to the rise in environmental pollution, which has increased
Further, the report states that a major factor that could hamper market growth is the low diagnosis rate
of COPD. It is difficult for physicians to recognize COPD at an early stage as the first symptoms of the
disease include common problems such as a cough, sputum production, and shortness of breath. Thus,
the diagnosis rate is only about one-third of the prevalent cases. This low diagnosis of COPD can be
attributed to the lack of physician’ s awareness about the risk factors, symptoms, and biomarkers of the
The study was conducted using an objective combination of primary and secondary information
including inputs from key participants in the industry. The report contains a comprehensive market and
About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China
Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases,
including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of
bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact
etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling
pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get
worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.
The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of
LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly
10% of the population in the region who are over the age of 40 years has COPD. The disease is expected
to become one of the leading causes of death in the country by 2020. Lack of awareness about the
disease and its treatment options affects the growth of the market in this region.
Technavio’ s analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow
at a CAGR of 15.56% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary
disease drugs market in China for 2016-2020. To calculate the market size, Technavio considers the
revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs
globally. The report does not include revenue generated from the aftermarket service of the product.
The market is divided into the following segments based on drug class:
• Bronchodilators
• Phosphodiesterase-4 (PDE-4) inhibitors
• Steroids
• Combination therapies
Technavio's report, Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China 2016-2020,
has been prepared based on an in-depth market analysis with inputs from industry experts. The report
covers the market landscape and its growth prospects over the coming years. The report also includes a
discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Boehringer Ingelheim
• Merck
• Novartis
Other prominent vendors
• Ache Laboratorios Farmaceuticos
• Almirall
• Aquinox Pharmaceuticals
• Ario Pharma
• BioMarck Pharmaceuticals
• Gilead Sciences
• Mereo BioPharma Group
• Mylan
• Orion
• Pearl Therapeutics
• Prosonix
• Teva Pharmaceutical Industry
• Theravance Biopharma
• Theron Pharmaceuticals
• Verona Pharma
• Xention
• ZAI Lab
Market driver
• Increase in environmental pollution
• For a full, detailed list, view our report
Market challenge
• Low diagnosis rate
• For a full, detailed list, view our report
Market trend
• Increased focus on combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’ s time when you purchase this market report. Details are
provided within the report.
Request for discount @
Table Of Content
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: COPD: An overview
• Causes and risk factors
• Symptoms
• Diagnosis
• Management
PART 06: China-Country snapshot
• Social and economic conditions
• Healthcare reform
• Healthcare infrastructure
PART 07: Pharmaceutical industry in China
• Market overview
• Major pharmaceutical vendors in China
• Opportunities for global and local vendors
• Drug approval process in China
PART 08: Drug pricing and reimbursement
• Market-driven drug pricing strategy
• Scrutinization of illegal pricing of drugs
PART 09: Pipeline portfolio
PART 10: Global respiratory drugs market
• Market overview
• Global COPD drugs market
PART 11: Market landscape
• COPD drugs market in china
• Five forces analysis
PART 12: Market segmentation by drug class
• Bronchodilators
• PDE-4 inhibitors
• Steroids
• Combination therapies
• Other medications
PART 13: Market drivers
• Increase in prevalence of smoking
• Rise in healthcare expenditure
• Increase in environmental pollution
PART 14: Impact of drivers
To Get Request Sample for this Reports:
For more information content with us;
Sam Collins
Market Reports Center 1-646-883-3044 (US) [email protected]
matthewjlarue341   document Email
Health and Medicine
File Size
407 KB
Report inappropriate content